翻译：
现代病理学杂志
乳腺导管原位癌的Oncotype DX检测方法用以检测导管原位癌病人的局部复发风险。检测结果有助于筛选低风险的导管原位癌病人，保守手术后行放射治疗。检测的基因包括5个增殖基因、孕激素受体（PR）和GSTM-1。我们的目的是判定导管原位癌的PR、核分裂计数或其它病理特征是否能预测导管原位癌Oncotype DX检测评分。
我们对46例导管原位癌进行Oncotype DX检测评分。除常规病理信息外，计数导管原位癌的核分裂象，记录导管原位癌周围是否有密集的慢性炎细胞浸润。我们发现：PR ≥90%(P=0.004)、核分裂计数≤1(P=0.045)、雌激素受体≥90%(P=0.046)、低核级(P<0.0001)与导管原位癌Oncotype DX检测低评分相关。
导管原位癌周围密集的慢性炎细胞浸润与Oncotype DX检测高评分相关(P=0.034)。PR ≥90%、核分裂象≤1且导管原位癌周围缺乏密集慢性炎细胞浸润的病例有13例，Oncotype DX检测全部为低评分（特异性100%）。?
低评分不见于至少有以下2项的病例中：PR阴性、核分裂象>1和/或导管原位癌周围有密集的慢性炎细胞浸润（特异性100%）。我们的研究提示，联合运用PR(≥90%或阴性)、核分裂计数（≤1或>1）和导管原位癌周围密集的慢性炎细胞浸润这三个指标，可以预测乳腺导管原位癌Oncotype DX检测评分，核分裂计数和免疫反应的评估可以为乳腺导管原位癌提供预后信息。
原文：
Correlation of histopathologic features of ductal carcinoma in situ of the breast with the oncotype DX DCIS score.
Knopfelmacher A,Fox J,Lo Y,Shapiro N,Fineberg S
Modern Pathology； Sep 2015; 28 (9): 1152 - 1281:1167-73?
The Oncotype DX Breast Cancer Assay for ductal carcinoma in situ is used to determine local recurrence risk in patients with ductal carcinoma in situ. The results help select patients with low-risk ductal carcinoma in situ who could forgo radiation therapy after conservative surgery.?
The genes assessed include five proliferation genes, progesterone receptor (PR), and GSTM-1. Our objective was to determine if PR, mitotic counting, or any other pathologic feature of ductal carcinoma in situ could predict the Oncotype DX DCIS Score. We identified 46 cases of ductal carcinoma in situ with a Oncotype DX DCIS Score. In addition to information obtained from routine pathology, we counted mitotic figures in the ductal carcinoma in situ and noted presence of dense chronic inflammatory infiltrate surrounding ductal carcinoma in situ.?
We found that PR ≥90% (P=0.004), mitotic count ≤1 (P=0.045), estrogen receptor ≥90% (P=0.046), and low nuclear grade (P<0.0001) were associated with a low score. Dense chronic inflammation surrounding ductal carcinoma in situ was associated with a high score (P=0.034).All 13 cases with PR ≥90%, ≤1 mitotic figure and absence of dense chronic inflammation around ductal carcinoma in situ had a low score (100% specificity).?
A low score was not observed in any case with at least two of the following-negative PR, >1 mitotic figure, and/or presence of dense chronic inflammation around ductal carcinoma in situ (100% specificity). Our study suggests using a combination of PR (≥90% vs negative) with mitotic count in ductal carcinoma in situ (≤1 vs >1) and dense chronic inflammation around ductal carcinoma in situ one could predict the Oncotype DX DCIS score. Mitotic counting and evaluation of immune response might provide prognostic information in ductal carcinoma in situ.
